Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4618 Target Snapshot

Leukotriene A-4 hydrolase · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,264Compounds
158Assays
5Approved Drugs
1,620.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Leukotriene A-4 hydrolase shows clinical signal disease relevance led by acne. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P09960. Start with acne, then reuse UniProt P09960 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with acne, then reuse UniProt P09960 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
acne

Leukotriene A-4 hydrolase shows clinical signal disease relevance led by acne. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with acne because it currently carries clinical signal support. Linked drugs include ACEBILUSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Leukotriene A-4 hydrolase as ChEMBL target CHEMBL4618, mapped to UniProt P09960. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Leukotriene A-4 hydrolase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4618
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P09960
Leukotriene A-4 hydrolase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Leukotriene A-4 hydrolase is the right protein anchor across sources, using UniProt P09960 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why acne is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameLeukotriene A-4 hydrolase
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP09960
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelLeukotriene A-4 hydrolase
UniProt AccessionP09960
Component TypeProtein
Sequence Length611 aa

Leukotriene A-4 hydrolase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Leukotriene A-4 hydrolase, mapped to UniProt P09960. Sequence length is 611 aa.

Mapped IDP09960
Review nameLeukotriene A-4 hydrolase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Leukotriene A-4 hydrolase shows clinical signal disease relevance led by acne. 3 more disease programs remain visible in the same review block.

Clinical signal Phase II
acne
1 linked drug · 1 direct · 1 efficacy
Linked drugACEBILUSTAT
Clinical signal Phase II
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugACEBILUSTAT
Clinical signal Phase II
cystic fibrosis
1 linked drug · 1 direct · 1 efficacy
Linked drugACEBILUSTAT
Clinical signal Phase II
lymphedema
1 linked drug · 1 direct · 1 efficacy
Linked drugACEBILUSTAT
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with acne because it currently carries clinical signal support. Linked drugs include ACEBILUSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseacne
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
1
Phase III
6
Phase II
Assay Mix

Activity Type Distribution

IC501,554.0
KI39.0
EC508.0
KD19.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5924242 10.38 IC50 0.042 Preclinical
CHEMBL6060058 10.15 IC50 0.07 Preclinical
CHEMBL5797467 10.1 IC50 0.08 Preclinical
CHEMBL6015103 10.05 IC50 0.09 Preclinical
CHEMBL5990393 10.05 IC50 0.09 Preclinical
CHEMBL5904849 10.05 IC50 0.09 Preclinical
CHEMBL5780202 10.05 IC50 0.09 Preclinical
CHEMBL5862086 10.0 IC50 0.1 Preclinical
CHEMBL5836580 10.0 IC50 0.1 Preclinical
CHEMBL5809166 10.0 IC50 0.1 Preclinical
Distribution

pChEMBL Value Distribution

75
5.0
61
5.5
130
6.0
187
6.5
173
7.0
127
7.5
118
8.0
164
8.5
198
9.0
89
9.5
pChEMBL
Approved Drugs

Approved Drugs

ZILEUTON
CHEMBL93
Approved 1996
Properties Compare Identifier
CAPTOPRIL
CHEMBL1560
Approved 1981
Properties Compare Identifier
Assay Landscape

Assay Landscape

158
Total Assays
1,173
Tested Compounds
3
Assay Types
Binding — 153 assays, 1,173 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 66 900 8.0
cell-based format 39 88 7.4
assay format 28 68 5.0
tissue-based format 20 117 7.0
Functional — 3 assays, 96 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 36 6.5
tissue-based format 1 60 6.3
ADME — 2 assays, 3 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 3 5.9

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine